Bicalutamide with or without metformin for biochemical recurrence in prostate cancer patients (BIMET-1).

Marijo Bilusic,Matthew Zibelman,Pooja Ghatalia,Susan Wroblewski,Ravi A. Madan,Fatima Karzai,William L. Dahut,James L. Gulley,Elizabeth R. Plimack,Daniel M. Geynisman

Bicalutamide with or without metformin for biochemical recurrence in prostate cancer patients (BIMET-1).

2020

Marijo Bilusic
Matthew Zibelman
Pooja Ghatalia
Susan Wroblewski
Ravi A. Madan
Fatima Karzai
William L. Dahut
James L. Gulley
Elizabeth R. Plimack
Daniel M. Geynisman

85Background: Metformin (MET) may play a role as an anti-proliferative and anti-carcinogenic agent. Epidemiological studies have demonstrated that MET is associated with decreased prostate cancer (...

Keywords:

Oncology
Prostate cancer
Pathology
Biochemical recurrence
Metformin
Epidemiology
Medicine
Bicalutamide
Internal medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations